In a similar setting, CDK2i BLU‐222 is undergoing dose escalation and has shown a partial response in one out of 12 BC patients, a case of HR+/HER2−–mBC that had received palbociclib, abemaciclib and capecitabine.81 This evidence concerns the gene ERBB2 and breast cancer.